Search
Filter Results
- Resource Type
- Article1
- Book1
- Book Digital1
- Article Type
- Clinical Trial1
- Clinical Study1
- Controlled Clinical Trial1
- Result From
- Lane Catalog1
- PubMed1
-
Year
- Journal Title
- Cancer Treat Rep1
Search Results
Sort by
- Book[edited by] Subba R. Digumarthy, Suhny Abbara, Jonathan H. Chung.Digital Access ClinicalKey 2019
- ArticleYap HY, Salem P, Hortobagyi GN, Bodey GP, Buzdar AU, Tashima CK, Blumenschein GR.Cancer Treat Rep. 1978 Mar;62(3):405-8.Twenty-six patients with metastatic breast cancer received cis-dichlorodiammineplatinum(II) either as a single dose of 100 mg/m2 iv every 3--4 weeks or as a continuous 5-day infusion of 20 mg/m2/day at 4-week intervals. Fourteen patients were treated with the single-dose schedule and 12 patients were treated with the continuous 5-day infusion. No significant response was observed with either dose schedule. Aside from a reduction in the frequency and severity of gastrointestinal toxicity with the continuous 5-day infusion, no real difference was seen with regard to renal and hematologic toxicity with either dose schedule.